Biocon Limited has successfully completed a Qualified Institutions Placement (QIP), raising Rs 4.15 billion (approximately USD 460 million) through the issuance of 12,664,585 equity shares at an issue price of Rs 368.35 per share, including a premium of Rs 363.35. The QIP opened on 12 January 2026 and closed on 14 January 2026, witnessing strong demand from domestic and international investors, reflecting broad confidence in Biocon’s growth strategy and differentiated biosimilars portfolio. The proceeds from the fundraise will primarily be used to meet the cash consideration payable to Mylan Inc. (Viatris) for the acquisition of minority shareholding in Biocon Biologics Limited. The company’s Board has approved a strategic corporate action to acquire all remaining minority stakes held by Viatris, which will result in Biocon Biologics becoming a wholly owned subsidiary. This integration marks a significant step in Biocon’s long-term strategy to strengthen its leadership across therapeutic segments such as diabetes, oncology and immunology through an expanded portfolio of biosimilar insulins, biologics and GLP-1 products. The acquisition process is expected to be completed by 31 March 2026. The QIP attracted participation from domestic mutual funds, insurance companies and foreign institutional investors. Interest was recorded from 39 investors, with allocations made to 31 participants, including several leading institutional names across India and global markets. Net proceeds will be utilised towards: Payment to Viatris for acquisition of Biocon Biologics shares Repayment of debt linked to the acquisition Funding for redemption of compulsorily convertible debentures held by Biocon Biologics General corporate purposes The fundraise had received prior shareholder approval at the company’s Extraordinary General Meeting held on 31 December 2025. Kotak Mahindra Capital, HSBC Securities and Capital Markets, J.P. Morgan India and Morgan Stanley India acted as Book Running Lead Managers for the QIP. Legal counsel for Biocon included Amarchand Mangaldas & Co., while Linklaters Singapore and JSA Advocates advised the lead managers.